|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
The members of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins are key regulators of the intrinsic apoptotic pathway; dysregulation of this pathway leads to pathologic survival of cancer cells.
|
31764121 |
2020 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ovarian gene expressions of angiotensin converting enzyme 2 (ACE2), Mas receptor, tumor necrosis factor alpha (TNF-α) and B-cell leukemia/lymphoma-2 (BCL-2) were estimated.
|
31494171 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tested parameters included, estimation of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and glucose levels, testicular samples for histopathology and estimation of malondialdehyde (MDA), total antioxidant capacity (TAC), and B-cell leukemia/lymphoma-2 (BCL-2) levels as well as sperm count and motility.
|
30317639 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ESCs: endometrial stromal cells; 17β-E2: 17β-Estradiol; EMT: epithelial-mesenchymal transition; CASP3: caspase 3; BCL2: B cell leukemia/lymphoma 2; VEGFA: vascular endothelial growth factor A; lncRNA: long non-coding RNA; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; RT-qPCR: reverse transcription-quantitative polymerase chain reaction.
|
30608887 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, GFX could activate the caspase-8, caspase-9, and caspase-3, induce MTP disruption, downregulate B-cell leukemia-2 (Bcl-2) and B-cell leukemia-XL (Bcl-XL), and upregulate Bcl-2 assaciated X protein (Bax), Bcl-2-associated death promoter (Bad), Bcl-2 interacting domain (Bid) and cytoplasmic cytochrome C in SFs, suggesting that caspase-dependent extrinsic and intrinsic pathways were related to GFX-contributed apoptosis of SFs.
|
31637186 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Signal transduction mechanism studies indicated that exposure to Cu-NPs activated caspases 3, 8, and 9 and BH3 interacting domain death agonist (tBid), reduced B cell leukemia/lymphoma 2 (Bcl-2) expression, and increased the expression of apoptotic peptidase activating factor 1 (Apaf-1), BCL2-associated X, apoptosis regulator (Bax), and cytochrome c. A microarray analysis revealed significant alterations in the expression of 963 genes; of these, 622 were upregulated and 341 were downregulated.
|
30556269 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of proteins related to apoptosis, cysteinyl aspartate-specific proteinase 12 (caspase-12) and B-cell leukemia 2 (Bcl-2), was measured by western blot.
|
30704457 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells.
|
31293422 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the apoptosis rate and the levels of apoptosis marker proteins including B cell leukemia/lymphoma 2 (Bcl2) and Bcl2-associated X protein (Bax) were also measured and the results showed that Cd-induced apoptosis was markedly inhibited by Tre treatment.
|
31650140 |
2019 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic apoptotic pathway is fundamental to the pathophysiology of many hematologic malignancies.
|
30012635 |
2018 |
|
Leukemia, B-Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
B cell leukemia/lymphoma-2 (Bcl-2) suppresses apoptosis by binding the BH3 domain of proapoptotic factors and thereby regulating mitochondrial membrane potential (MMP).
|
28843007 |
2018 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was shown that high glucose significantly increased the protein expression of BAX (Bcl-2 Associated X protein) and Caspase-3 and decreased Bcl2 (B-Cell Leukemia/Lymphoma 2) protein level in RAECs, which was normalized by argirein medication.
|
30135489 |
2018 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to CC3a staining and expression analysis of Bax (B-cell leukemia 2-associated X) and Bcl-2 (B-cell leukemia 2) genes, MSCs attenuated increases in apoptosis postburn.
|
30260837 |
2018 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apoptosis was evidenced by enhanced cleavage of Caspase-8/-9/-3 and poly (ADP-ribose) polymerase (PARP), and reduced anti-apoptotic proteins, including B-cell leukemia/lymphoma 2 (Bcl-2), mantle cell lymphoma (Mcl)-1, and Survivin.
|
28950661 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, PCSK9 siRNA repressed the increase of cytochrome C (cyto C), caspase-3, and B-cell leukemia/lymphoma 2 (Bcl-2)-associated X (Bax) expressions induced by IR and promoted Bcl-2 expression, which might partially interpret the radioprotective role of PCSK9 siRNA in PCa cells.
|
28442922 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
The B-cell leukemia/lymphoma-2 (BCL-2) family of proteins governs the intrinsic pathway of mitochondrial apoptosis.
|
28724540 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
B-cell leukemia/lymphoma 2 (Bcl-2) family proteins regulate apoptotic pathway that can be targeted with small molecule inhibitors.
|
28586007 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
HgCl2 exposure led to increased Bcl-associated X protein (Bax), and decreased Bcl-2-related protein long form of Bcl-x (Bcl-xL) and B-cell leukemia/lymphoma-2 (Bcl-2) expression, leading to an increased Bax/Bcl-2 ratio.
|
28498799 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes.
|
28095146 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In cells treated with HQ, inhibition of PARP‑1 increased the expression of B cell leukemia/lymphoma 2 (Bcl‑2), increased ATP production and reduced reactive oxygen species (ROS) production relative to the levels observed in cells treated with HQ alone.
|
28983606 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BCL2-associated X protein (BAX) and BCL2 antagonist/killer 1 (BAK1), B-cell leukemia/lymphoma 2 (BCL2) family members, mediate mitochondrial damage to generate ROS after SINV infection.
|
28213497 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutrophil transcriptome analysis revealed that decreased apoptosis of TTP-deficient neutrophils was specifically associated with elevated expression of myeloid cell leukemia 1 (Mcl1) but not other antiapoptotic B cell leukemia/lymphoma 2 (Bcl2) family members.
|
28504646 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, ND augmented the hippocampal levels of phosphorylated signal transducer and activator of transcription-3 (p-STAT3) and B cell leukemia/lymphoma-2 (Bcl-2) anti-apoptotic protein while diminished nuclear factor-kappaB (NF-κB) and caspase-3 (casp-3) expression.
|
26897372 |
2017 |
|
Leukemia, B-Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
As PA raised it also raised the mRNA and protein expressions of caspase-3, caspase-8, caspase-9, Bax (Bcl-2 assaciated X protein), p53, p21, IκB-α (inhibitor of NF-κB alpha), Fas (factor associated suicide), FasL (factor associated suicide ligand), TIMP-1 (tissue inhibitor of metalloproteinases 1), TIMP-2 (tissue inhibitor of metalloproteinases 2) and decrease Bcl-2 (B cell leukemia 2), Bcl-xL (B cell leukemia extra large), HIAP-1 (cIAP-1, cellular inhibitor of apoptosis 1), HIAP-2 (cIAP-2, cellular inhibitor of apoptosis 2), NF-κB (nuclear factor kappa B), COX-2 (cyclooxygenase 2), iNOS (inducible nitric oxide synthase), MMP-2 (metalloproteinase 2), MMP-9 (metalloproteinase 9), EGF (epidermal growth factor), EGFR (epidermal growth factor receptor), VEGF (vascular endothelial growth factor), Fit-1 (VEGFR-1, vascular endothelial growth factor receptor 1).
|
28978315 |
2017 |